RECRUITING

A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Talk to us

Conditions

Eosinophilic Esophagitis (EoE)

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab). The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE. Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward. Patient questionnaires will measure the following: * How EoE makes one feel * EoE signs and/or symptoms, eg, how difficult it is to swallow * How EoE affects quality-of-life * How EoE impacts aspects of daily life * How EoE symptoms have changed throughout the study

Official Title

A U.S. Registry of Eosinophilic Esophagitis Patients Treated With DUPIXENT® As Standard of Care

Quick Facts

Study Start:2024-11-22
Study Completion:2030-05-22
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06693531

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Year
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  2. 2. Participants aged ≥12 years and caregivers or legal guardians of participants aged \<12 years must be able to understand and complete registry-related questionnaires
  1. 1. Patients who have a contraindication to DUPIXENT® according to the USPI
  2. 2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
  3. 3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

Contacts and Locations

Study Contact

Clinical Trials Administrator
CONTACT
844-734-6643
clinicaltrials@regeneron.com

Principal Investigator

Clinical Trial Management
STUDY_DIRECTOR
Regeneron Pharmaceuticals

Study Locations (Sites)

Phoenix Childrens Hospital
Phoenix, Arizona, 85016
United States
Arizona Digestive Health/GI Alliance
Sun City, Arizona, 85351
United States
Arkansas Childrens Hospital
Little Rock, Arkansas, 72202
United States
Scripps Clinic
La Jolla, California, 92037
United States
University of California Los Angeles (UCLA)
Los Angeles, California, 90024
United States
University of Southern California Keck School of Medicine
Los Angeles, California, 90033
United States
University of California, San Francisco
Oakland, California, 94609
United States
University of California San Francisco (UCSF)
San Francisco, California, 94115
United States
Childrens Hospital Colorado
Aurora, Colorado, 80045
United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, 80045
United States
Rocky Mountain Gastroenterology
Littleton, Colorado, 80120
United States
UConn Health - The Carole and Ray Neag Comprehensive Cancer Center
Farmington, Connecticut, 06030
United States
Yale School of Medicine
New Haven, Connecticut, 06510
United States
Gastroenterology of Greater Orlando
Orange City, Florida, 32763
United States
Orlando Health
Orlando, Florida, 32806
United States
Emory Healthcare, Emory Clinic
Atlanta, Georgia, 30322
United States
GI Care for Kids LLC
Atlanta, Georgia, 30342
United States
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, 60611
United States
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, 60611
United States
Comprehensive Gastrointestinal Health, LLC
Libertyville, Illinois, 60048
United States
NorthShore University Health System
Skokie, Illinois, 60077
United States
Kansas Gastroenterology LLC
Wichita, Kansas, 67226
United States
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky, 42301
United States
Boston Specialists
Boston, Massachusetts, 02111
United States
Massachusetts General Hospital
Boston, Massachusetts, 02114
United States
Boston Childrens Hospital
Boston, Massachusetts, 02115
United States
Mayo Clinic
Rochester, Minnesota, 55905
United States
GI Associates and Endoscopy Center
Flowood, Mississippi, 39232
United States
Kansas City VA Medical Center
Kansas City, Missouri, 64128
United States
Washington University in Saint Louis
St Louis, Missouri, 63110
United States
Allergy Partners of N.J., P.C.
Ocean City, New Jersey, 07712
United States
Steven And Alexandra Cohen Children's Medical Center Of New York
Lake Success, New York, 11042
United States
Weil Cornell Medicine NYP
New York, New York, 10021
United States
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
United States
Gastroenterology Group of Rochester LLP
Rochester, New York, 14618
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Duke University
Durham, North Carolina, 27710
United States
Atrium Health / Wake Forest University School of Medicine
Winston-Salem, North Carolina, 27157
United States
Great Lakes Gastroenterology Research, LLC
Mentor, Ohio, 44060
United States
Susquehanna Research Group
Camp Hill, Pennsylvania, 17011
United States
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Medical University of South Carolina
Charleston, South Carolina, 29425
United States
Palmetto Gastroenterology Clinical Research
Summerville, South Carolina, 29486
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
GI Alliance
Southlake, Texas, 76092
United States
Tanner Clinic
Layton, Utah, 84041
United States
University of Utah
Salt Lake City, Utah, 84132
United States
University of Virginia
Charlottesville, Virginia, 22908
United States
Seattle Children's Home Health Company
Seattle, Washington, 98105
United States
Washington Gastroenterology, GIA
Tacoma, Washington, 98405
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Regeneron Pharmaceuticals

  • Clinical Trial Management, STUDY_DIRECTOR, Regeneron Pharmaceuticals

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-11-22
Study Completion Date2030-05-22

Study Record Updates

Study Start Date2024-11-22
Study Completion Date2030-05-22

Terms related to this study

Additional Relevant MeSH Terms

  • Eosinophilic Esophagitis (EoE)